Modality
Fusion Protein
MOA
USP1i
Target
TIM-3
Pathway
DDR
Wet AMD
Development Pipeline
Preclinical
Jun 2021
→ May 2031
PreclinicalCurrent
NCT07639463
2,566 pts·Wet AMD
2021-06→2031-05·Recruiting
2,566 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-025.1y awayInterim· Wet AMD
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2031-05-02 · 5.1y away
Wet AMD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07639463 | Preclinical | Wet AMD | Recruiting | 2566 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |